JP2012505235A5 - - Google Patents

Download PDF

Info

Publication number
JP2012505235A5
JP2012505235A5 JP2011531168A JP2011531168A JP2012505235A5 JP 2012505235 A5 JP2012505235 A5 JP 2012505235A5 JP 2011531168 A JP2011531168 A JP 2011531168A JP 2011531168 A JP2011531168 A JP 2011531168A JP 2012505235 A5 JP2012505235 A5 JP 2012505235A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently
heterocyclyl
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011531168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012505235A (ja
JP5560278B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/059968 external-priority patent/WO2010042699A1/en
Publication of JP2012505235A publication Critical patent/JP2012505235A/ja
Publication of JP2012505235A5 publication Critical patent/JP2012505235A5/ja
Application granted granted Critical
Publication of JP5560278B2 publication Critical patent/JP5560278B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011531168A 2008-10-09 2009-10-08 キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル Expired - Fee Related JP5560278B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10404508P 2008-10-09 2008-10-09
US61/104,045 2008-10-09
PCT/US2009/059968 WO2010042699A1 (en) 2008-10-09 2009-10-08 Imidazopyridazinecarbonitriles useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012505235A JP2012505235A (ja) 2012-03-01
JP2012505235A5 true JP2012505235A5 (enExample) 2012-08-09
JP5560278B2 JP5560278B2 (ja) 2014-07-23

Family

ID=41718919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011531168A Expired - Fee Related JP5560278B2 (ja) 2008-10-09 2009-10-08 キナーゼ阻害剤として有用なイミダゾピリダジンカルボニトリル

Country Status (27)

Country Link
US (3) US8252795B2 (enExample)
EP (1) EP2350081B1 (enExample)
JP (1) JP5560278B2 (enExample)
KR (1) KR20110075010A (enExample)
CN (1) CN102245609B (enExample)
AR (1) AR073818A1 (enExample)
AU (1) AU2009302360B2 (enExample)
BR (1) BRPI0920135A2 (enExample)
CA (1) CA2739782A1 (enExample)
CL (1) CL2011000777A1 (enExample)
CO (1) CO6361936A2 (enExample)
CY (1) CY1114539T1 (enExample)
DK (1) DK2350081T3 (enExample)
EA (1) EA018163B1 (enExample)
ES (1) ES2426951T3 (enExample)
HR (1) HRP20130787T1 (enExample)
IL (1) IL211693A (enExample)
MX (1) MX2011003304A (enExample)
NZ (1) NZ591712A (enExample)
PE (1) PE20110411A1 (enExample)
PL (1) PL2350081T3 (enExample)
PT (1) PT2350081E (enExample)
SI (1) SI2350081T1 (enExample)
SM (1) SMT201300109B (enExample)
TW (1) TWI491610B (enExample)
WO (1) WO2010042699A1 (enExample)
ZA (1) ZA201102423B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240488B1 (en) * 2008-02-06 2016-11-02 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
EP2651944B1 (en) 2010-12-17 2015-09-23 Bayer Intellectual Property GmbH Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
PE20160156A1 (es) 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
WO2017223432A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals Ck2 inhibitors, compositions and methods thereof
MA45940B1 (fr) * 2016-08-10 2024-12-31 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US11299494B2 (en) 2016-11-17 2022-04-12 Bristol-Myers Squibb Company Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
CA3079786A1 (en) 2017-10-24 2019-05-02 The Broad Institute, Inc. 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2019128871A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
WO2019128872A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 一种具有杀虫活性的吡唑酰胺类化合物及其应用
CN109988150B (zh) 2017-12-29 2022-04-12 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
JP7377207B2 (ja) * 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
MX2021000293A (es) 2018-07-09 2021-07-15 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos antihelminticos.
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020180907A1 (en) * 2019-03-05 2020-09-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
JP7637630B2 (ja) 2019-03-19 2025-02-28 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 駆虫性アザベンゾチオフェンおよびアザベンゾフラン化合物
US20240307362A1 (en) 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
EP3958865B1 (en) 2019-04-24 2025-12-10 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
GEP20247648B (en) 2019-04-24 2024-07-25 Bayer Ag 4h-pyrrolo[3,2-c]pyridin-4-one compounds
WO2021198020A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
PH12022553222A1 (en) 2020-05-29 2024-02-12 Boehringer Ingelheim Animal Health Usa Inc Anthelmintic heterocyclic compounds
JP2024505284A (ja) 2021-02-03 2024-02-05 サノフイ イミダゾ［４，５－ｄ］ピリダジンの誘導体、それらの製造およびそれらの治療用途
AR127495A1 (es) 2021-11-01 2024-01-31 Boehringer Ingelheim Vetmedica Gmbh Compuestos de pirrolopiridazina como antihelmínticos
JP2025508323A (ja) * 2022-01-25 2025-03-26 キネート バイオファーマ インク． Ｃｄｋ４／６キナーゼの阻害薬
US20260055114A1 (en) * 2022-08-18 2026-02-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases
CN115947756B (zh) * 2022-12-13 2025-08-01 西湖大学 一种芳基卤代物和多氟烷基醇直接偶联合成多氟烷基芳基醚的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900389T2 (xx) 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
RU2005118421A (ru) 2002-11-15 2006-01-20 Айденикс (Кайман) Лимитед (Ky) 2'-разветвленные нуклеозиды и мутация flaviviridae
PL380764A1 (pl) * 2003-12-31 2007-03-19 Schering-Plough Ltd. Kontrolowanie pasożytów u zwierząt za pomocą stosowania imidazo [1,2-b] pirydazynowych pochodnych
EP1713784A1 (en) 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑－类抑制剂
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
US20070185063A1 (en) 2005-08-23 2007-08-09 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) * 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
BRPI0714665A2 (pt) * 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1911451A1 (en) * 2006-10-10 2008-04-16 INSERM (Institut National de la Santé et de la Recherche Medicale) Protein-kinase CK2 inhibitors and their therapeutic applications
WO2008052733A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
PE20090215A1 (es) * 2007-05-09 2009-03-30 Novartis Ag Compuestos derivados de imidazopiridazinas como inhibidores de cinasa
EP2240488B1 (en) * 2008-02-06 2016-11-02 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Similar Documents

Publication Publication Date Title
JP2013523756A5 (enExample)
JP2011511095A5 (enExample)
IL268030B2 (en) Bicyclics as allosteric shp2 inhibitors
JP2019518766A5 (enExample)
RU2020102453A (ru) Фармацевтические композиции
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
HRP20131051T1 (hr) Inhibitori proteinskih kinaza
JP2010510215A5 (enExample)
JP2019512478A5 (enExample)
JP2012153722A5 (enExample)
NZ710745A (en) Pyrrolobenzodiazepines and conjugates thereof
JP2005524631A5 (enExample)
JP2017511321A5 (enExample)
JP2014533299A5 (enExample)
JP2017531041A5 (enExample)
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2014507421A5 (enExample)
HK1208217A1 (en) Pyrrolobenzodiazepines
JP2013520424A5 (enExample)
JP2009542683A5 (enExample)
JP2013538213A5 (enExample)
JP2021534097A5 (enExample)
JP2016503414A5 (enExample)
JP2013199483A5 (enExample)
JP2013528619A5 (enExample)